Family History and Relapse in Pediatric Acute Myeloid Leukemia

We report the epidemiology and characteristics of acute myeloid leukemia and outcomes of its treatment with the AML‐BFM 83 protocol at the Mahak Pediatric Cancer Treatment and Research Center, Tehran, Iran, from 2007 to 2012. A positive family history of cancer or leukemia was associated with the ri...

Full description

Saved in:
Bibliographic Details
Published in:Pediatric blood & cancer 2015-12, Vol.62 (12), p.2235-2237
Main Authors: Mehrvar, Azim, Tashvighi, Maryam, Faranoush, Mohammad, Reinhardt, Dirk, Niktoreh Mofrad, Naghmeh, Hedayati Asl, Amir Abbas, Alebouyeh, Mardawij
Format: Article
Language:English
Subjects:
acute myeloid leukemia
Adolescent
Antineoplastic Combined Chemotherapy Protocols - administration & dosage
Child
Child, Preschool
Cytarabine - administration & dosage
Daunorubicin - administration & dosage
Disease-Free Survival
Etoposide - administration & dosage
Female
Hematology
Humans
Infant
Leukemia, Myeloid, Acute - drug therapy
Leukemia, Myeloid, Acute - mortality
Male
Oncology
Pediatrics
Recurrence
survival
Survival Rate
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We report the epidemiology and characteristics of acute myeloid leukemia and outcomes of its treatment with the AML‐BFM 83 protocol at the Mahak Pediatric Cancer Treatment and Research Center, Tehran, Iran, from 2007 to 2012. A positive family history of cancer or leukemia was associated with the risk of relapse (family history of cancer in relapse: n = 11; 61%, P = 0.136, leukemia: n = 7; 39%; P = 0.016). Treatment‐related mortality was 19% and associated with underweight patients (n = 5; 62.5%; P = 0.158). Event‐free and overall survivals were 36% (SE = 3.5) and 44% (SE = 3.4), respectively. These data suggest a possible relationship between family history and relapse rate. Pediatr Blood Cancer © 2015 Wiley Periodicals, Inc.
ISSN:1545-5009
1545-5017
DOI:10.1002/pbc.25649